financetom
Business
financetom
/
Business
/
Update: AptarGroup Shares Decline After Issuing Q4 Adjusted Earnings Guidance Below Expectations
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: AptarGroup Shares Decline After Issuing Q4 Adjusted Earnings Guidance Below Expectations
Oct 31, 2025 9:42 AM

12:18 PM EDT, 10/31/2025 (MT Newswires) -- (Updates with stock price movement in the headline and first paragraph.)

AptarGroup ( ATR ) shares fell over 11% in recent Friday trading after the company issued a lower-than-expected Q4 adjusted profit forecast, despite posting higher Q3 results that exceeded analyst estimates.

The company reported Q3 non-GAAP net income late Thursday of $1.62 per diluted share, up from $1.56 a year earlier.

Analysts polled by FactSet expected $1.57.

Revenue for the quarter ended Sept. 30 was $961.1 million, up from $909.3 million a year earlier.

Analysts surveyed by FactSet expected $953.5 million.

The company expects Q4 adjusted EPS of $1.20 to $1.28 per share. Analysts polled by FactSet expect $1.43.

Price: 110.13, Change: -14.23, Percent Change: -11.44

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Monopar Receives Clearance in Australia for Phase 1 Trial of Radiopharmaceutical in Advanced Cancers
Monopar Receives Clearance in Australia for Phase 1 Trial of Radiopharmaceutical in Advanced Cancers
Aug 21, 2024
08:50 AM EDT, 08/21/2024 (MT Newswires) -- Monopar Therapeutics ( MNPR ) said Wednesday it has received clearance from Australia's Human Research Ethics Committee to start a phase 1 therapeutic trial of its radiopharmaceutical MNPR-101-Lu. The MNPR-101-Lu trial will enroll patients with advanced solid cancers and will be a therapeutic follow-on study to its ongoing MNPR-101-Zr imaging and dosimetry trial,...
Ford Stock Charges Higher On EV Strategy Shift: What Investors Need To Know
Ford Stock Charges Higher On EV Strategy Shift: What Investors Need To Know
Aug 21, 2024
Ford Motor Co ( F ) shares are getting a boost Wednesday morning after the company announced plans to broaden its electrification strategy. What To Know: Ford announced that it’s taking additional actions to deliver a profitable, capital-efficient and growing electric vehicle business, including adjusting the company’s North America vehicle roadmap to offer a range of electrification options aimed at...
Nordson Closes Atrion Acquisition
Nordson Closes Atrion Acquisition
Aug 21, 2024
09:01 AM EDT, 08/21/2024 (MT Newswires) -- Nordson ( NDSN ) said Wednesday it has closed the acquisition of medical device manufacturer Atrion ( ATRI ) . In May, Nordson ( NDSN ) said it agreed to buy Atrion ( ATRI ) for $460 per share in cash. Price: 241.00, Change: +1.53, Percent Change: +0.64 ...
Atossa Therapeutics Doses First Patient in Breast Cancer Therapy Study
Atossa Therapeutics Doses First Patient in Breast Cancer Therapy Study
Aug 21, 2024
09:08 AM EDT, 08/21/2024 (MT Newswires) -- Atossa Therapeutics ( ATOS ) said Wednesday that it had dosed the first patient in a trial evaluating its experimental drug, (Z)-endoxifen, in combination with Eli Lilly's ( LLY ) abemaciclib as a neoadjuvant treatment for certain high-risk breast cancer patients. The study, which is part of the I-SPY network, will involve around...
Copyright 2023-2026 - www.financetom.com All Rights Reserved